These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8123241)

  • 1. Spasmodic dysphonia. Emotional status and botulinum toxin treatment.
    Murry T; Cannito MP; Woodson GE
    Arch Otolaryngol Head Neck Surg; 1994 Mar; 120(3):310-6. PubMed ID: 8123241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emotional symptoms are secondary to the voice disorder in patients with spasmodic dysphonia.
    Liu CY; Yu JM; Wang NM; Chen RS; Chang HC; Li HY; Tsai CH; Yang YY; Lu CS
    Gen Hosp Psychiatry; 1998 Jul; 20(4):255-9. PubMed ID: 9719906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of botulinum toxin type A injections on aerodynamic measures of spasmodic dysphonia.
    Adams SG; Durkin LC; Irish JC; Wong DL; Hunt EJ
    Laryngoscope; 1996 Mar; 106(3 Pt 1):296-300. PubMed ID: 8614192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of spasmodic dysphonia with botulinum toxin].
    Klap P; Marion MH; Perrin A; Fresnel-Elbaz E
    Ann Otolaryngol Chir Cervicofac; 1991; 108(8):477-82; discussion 482-3. PubMed ID: 1789624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The swallowing side effects of botulinum toxin type A injection in spasmodic dysphonia.
    Holzer SE; Ludlow CL
    Laryngoscope; 1996 Jan; 106(1 Pt 1):86-92. PubMed ID: 8544635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia.
    Adams SG; Hunt EJ; Irish JC; Charles DA; Lang AE; Durkin LC; Wong DL
    J Otolaryngol; 1995 Dec; 24(6):345-51. PubMed ID: 8699600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
    Hogikyan ND; Wodchis WP; Spak C; Kileny PR
    J Voice; 2001 Dec; 15(4):576-86. PubMed ID: 11792036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia.
    Troung DD; Rontal M; Rolnick M; Aronson AE; Mistura K
    Laryngoscope; 1991 Jun; 101(6 Pt 1):630-4. PubMed ID: 2041443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adductor spasmodic dysphonia and botulinum toxin treatment: the effect on well-being.
    Langeveld TP; Luteijn F; van Rossum M; Drost HA; Baatenburg de Jong RJ
    Ann Otol Rhinol Laryngol; 2001 Oct; 110(10):941-5. PubMed ID: 11642427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results.
    Adams SG; Hunt EJ; Charles DA; Lang AE
    J Otolaryngol; 1993 Jun; 22(3):171-5. PubMed ID: 8371328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin for treating spasmodic dysphonia (laryngeal dystonia): a systematic Cochrane review.
    Watts C; Nye C; Whurr R
    Clin Rehabil; 2006 Feb; 20(2):112-22. PubMed ID: 16541931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin injection for treatment of spasmodic dysphonia: experience at Srinagarind Hospital.
    Srirompotong S; Saeseow P; Taweesaengsuksakul R; Kharmwan S; Srirompotong S
    J Med Assoc Thai; 2006 Dec; 89(12):2077-80. PubMed ID: 17214059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal follow-up of adductor spasmodic dysphonia patients after botulinum toxin injection: quality of life results.
    Paniello RC; Barlow J; Serna JS
    Laryngoscope; 2008 Mar; 118(3):564-8. PubMed ID: 18216744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin injections for the treatment of spasmodic dysphonia.
    Watts CC; Whurr R; Nye C
    Cochrane Database Syst Rev; 2004; 2004(3):CD004327. PubMed ID: 15266530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonpharmacologic effects of botulinum toxin on the life quality of patients with spasmodic dysphonia.
    Anari S; Carding PN; Hawthorne MR; Deakin J; Drinnan MJ
    Laryngoscope; 2007 Oct; 117(10):1888-92. PubMed ID: 17690610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of methods of botulinum toxin injection for abductory spasmodic dysphonia.
    Meleca RJ; Hogikyan ND; Bastian RW
    Otolaryngol Head Neck Surg; 1997 Nov; 117(5):487-92. PubMed ID: 9374172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spasmodic dysphonia: new diagnosis and treatment opportunities.
    Cook MJ; Lewin JS
    Nurse Pract; 1994 Sep; 19(9):67-73. PubMed ID: 7816374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of botulinum toxin in the treatment of adductor spasmodic dysphonia.
    Whurr R; Lorch M; Fontana H; Brookes G; Lees A; Marsden CD
    J Neurol Neurosurg Psychiatry; 1993 May; 56(5):526-30. PubMed ID: 8505645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia.
    Adler CH; Bansberg SF; Krein-Jones K; Hentz JG
    Mov Disord; 2004 Sep; 19(9):1075-9. PubMed ID: 15372600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of botulinum toxin treatment for patients with spasmodic dysphonia.
    Benninger MS; Gardner G; Grywalski C
    Arch Otolaryngol Head Neck Surg; 2001 Sep; 127(9):1083-5. PubMed ID: 11556856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.